LEXINGTON, Mass.--(BUSINESS WIRE)--EPIX Pharmaceuticals, Inc. (NASDAQ: EPIX), a biopharmaceutical company focused on discovering and developing novel therapeutics through the use of its proprietary and highly efficient in silico drug discovery platform, announced today that it received notice from The NASDAQ Stock Market dated October 10, 2008 that it is not in compliance with NASDAQ Marketplace Rule 4450(b)(1)(A), which requires a listed security to maintain a minimum $50 million market capitalization for continued listing on The NASDAQ Global Market. This notice has no immediate effect on the company’s listing and its common stock will continue to trade on The NASDAQ Global Market.
